8 results on '"Hilde, Langseth"'
Search Results
2. Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia
- Author
-
Eleanor L, Watts, Aurora, Perez-Cornago, Georgina K, Fensom, Karl, Smith-Byrne, Urwah, Noor, Colm D, Andrews, Marc J, Gunter, Michael V, Holmes, Richard M, Martin, Konstantinos K, Tsilidis, Demetrius, Albanes, Aurelio, Barricarte, Bas, Bueno-de-Mesquita, Chu, Chen, Barbara A, Cohn, Niki L, Dimou, Luigi, Ferrucci, Leon, Flicker, Neal D, Freedman, Graham G, Giles, Edward L, Giovannucci, Gary E, Goodman, Christopher A, Haiman, Graeme J, Hankey, Jiaqi, Huang, Wen-Yi, Huang, Lauren M, Hurwitz, Rudolf, Kaaks, Paul, Knekt, Tatsuhiko, Kubo, Hilde, Langseth, Gail, Laughlin, Loic, Le Marchand, Tapio, Luostarinen, Robert J, MacInnis, Hanna O, Mäenpää, Satu, Männistö, E Jeffrey, Metter, Kazuya, Mikami, Lorelei A, Mucci, Anja W, Olsen, Kotaro, Ozasa, Domenico, Palli, Kathryn L, Penney, Elizabeth A, Platz, Harri, Rissanen, Norie, Sawada, Jeannette M, Schenk, Pär, Stattin, Akiko, Tamakoshi, Elin, Thysell, Chiaojung Jillian, Tsai, Shoichiro, Tsugane, Lars, Vatten, Elisabete, Weiderpass, Stephanie J, Weinstein, Lynne R, Wilkens, Bu B, Yeap, Naomi E, Allen, Timothy J, Key, Ruth C, Travis, Department of Public Health, HUS Comprehensive Cancer Center, and Department of Oncology
- Subjects
Male ,Cancer Research ,CALCULATED FREE TESTOSTERONE ,3122 Cancers ,Prostatic Neoplasms/epidemiology ,PSA ,Risk Factors ,Sex Hormone-Binding Globulin ,BINDING ,Sex Hormone-Binding Globulin/analysis ,Humans ,Testosterone ,SHBG ,Mendelian randomisation ,Cancer och onkologi ,FOCUS ,Prostate ,Prostatic Neoplasms ,MEN ,Mendelian Randomization Analysis ,prostate cancer ,Oncology ,aggressive prostate cancer ,Cancer and Oncology ,testosterone ,FINASTERIDE ,ICEP ,SENSITIVITY ,FOLLOW-UP ,Biomarkers - Abstract
Publisher Copyright: © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged
- Published
- 2022
3. Prediagnostic circulating levels of sex hormones and survival in esophageal adenocarcinoma
- Author
-
Jesper Lagergren, Eivind Ness-Jensen, Hilde Langseth, Shao-Hua Xie, Randi Elin Gislefoss, and Fredrik Mattsson
- Subjects
Adult ,Male ,gonadal steroid hormones ,Cancer Research ,Esophageal Neoplasms ,Population ,Physiology ,Cohort Studies ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Dehydroepiandrosterone sulfate ,Sex hormone-binding globulin ,Sex Hormone-Binding Globulin ,Humans ,Medicine ,education ,Testosterone ,Aged ,education.field_of_study ,adenocarcinoma ,biology ,business.industry ,Hazard ratio ,Middle Aged ,Survival Analysis ,mortality ,Prolactin ,Survival Rate ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Multivariate Analysis ,biology.protein ,prognosis ,Follicle Stimulating Hormone ,Luteinizing hormone ,business ,Body mass index ,Cancer Epidemiology - Abstract
Sex hormonal differences may contribute to the strong male predominance in esophageal adenocarcinoma (EAC), but whether sex hormone levels influence survival in EAC is unstudied. Our study aimed to assess associations between prediagnostic sex hormone levels and survival in EAC. In a population‐based cohort study, 244 male EAC patients from the Janus Serum Bank Cohort in Norway were followed up through 2018. Associations between prediagnostic serum levels of 12 sex hormone measures and disease‐specific mortality were assessed using multivariable Cox regression, providing hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age, calendar year, body mass index, tobacco smoking, physical activity and surgical resection. Higher levels of sex hormone‐binding globulin (SHBG) indicated decreased disease‐specific mortality (HR 0.68, 95% CI 0.44‐1.07, highest vs lowest tertile). In stratified analyses by surgery, such associations remained in nonoperated patients (HR 0.58, 95% CI 0.35‐0.96, highest vs lowest tertile), but not in operated patients. Higher levels of follicle‐stimulating hormone (FSH) were associated with increased disease‐specific mortality in an exposure‐response pattern; HRs for the middle and highest tertiles vs the lowest tertile were 1.35 (95% CI 0.89‐2.05) and 1.61 (95% CI 1.06‐2.43), respectively. No clear associations were observed with serum levels of dehydroepiandrosterone sulfate, luteinizing hormone, prolactin, testosterone, 17‐OH‐progesterone, progesterone, estradiol, androstenedione, testosterone:estradiol ratio or free testosterone index. These findings suggest that higher endogenous levels of SHBG and lower levels of FSH may increase the survival in EAC. The other 10 examined sex hormone measures may not influence the survival., What's new? Esophageal adenocarcinoma (EAC) occurs more frequently in men than women. Whether this pattern is linked to differences in sex hormone levels and whether such differences impact EAC survival remain unclear. In this study of male EAC patients in Norway, analyses of prediagnostic sex hormone measures uncovered associations between reduced disease‐specific mortality and increased sex hormone‐binding globulin and decreased follicle‐stimulating hormone levels. The associations were detected only in patients who had not undergone surgery. Ten other sex hormone measures also analyzed had no influence on survival. Additional investigation is needed to better understand relationships between sex hormone levels and EAC survival.
- Published
- 2020
4. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non‐Hodgkin lymphoma subtypes
- Author
-
Nathaniel Rothman, Qing Lan, Mark P. Purdue, Tom Kristian Grimsrud, Hilde Langseth, and Allan Hildesheim
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Chronic lymphocytic leukemia ,Follicular lymphoma ,Ki-1 Antigen ,Single sample ,Risk Assessment ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Biomarkers, Tumor ,Odds Ratio ,medicine ,Humans ,Longitudinal Studies ,Lymphoma, Follicular ,Aged ,Aged, 80 and over ,Norway ,business.industry ,Odds ratio ,Middle Aged ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,Confidence interval ,Tumor Necrosis Factor Receptor Superfamily, Member 7 ,Lymphoma ,Oncology ,Case-Control Studies ,030220 oncology & carcinogenesis ,Hodgkin lymphoma ,Female ,Multiple Myeloma ,business ,Cohort study - Abstract
Elevated pre-diagnostic serum levels of the immune activation markers sCD27 and sCD30 have been associated with non-Hodgkin lymphoma (NHL). However, the use of a single sample per participant in these studies has limited etiologic inferences. We report findings, overall and by NHL subtype, from a case-control analysis (422 cases, 434 controls) within the Janus Serum Bank with two samples per subject collected on average five years apart. Chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) was associated with elevated sCD27 in the later, but not earlier, pre-diagnostic sample (odds ratio [OR] 4.2, 95% confidence interval [CI] 1.5-11.6 and 1.7, 0.7-4.7 per log increase respectively) in analyses adjusting for both analytes, while follicular lymphoma (FL) was associated with elevated sCD30 in both the later and earlier samples (OR 2.9, 95% CI 1.4-4.4 and 2.3, 1.2-4.4 respectively). CLL/SLL cases were significantly more likely than controls to have higher sCD27 in the later vs. earlier sample (OR 1.4, 95% CI 1.1-1.9 per standard deviation increase); no such difference in sCD30 was apparent for FL. In a joint analysis, NHL cases were more likely than controls to have below-median sCD27 in the earlier sample and above-median sCD27 in the later sample (OR 1.5, 95% CI 1.0-2.3). For sCD30, the association between sCD30 and FL was confined to subjects with above-median analyte levels in both samples (OR 2.5, 95% CI 1.1-5.9). Our findings are compatible with elevated sCD27 representing a disease-induced effect and sCD30 representing a marker of increased FL susceptibility.
- Published
- 2019
5. Prediagnostic blood levels of organochlorines and risk of non‐Hodgkin lymphoma in three prospective cohorts in China and Singapore
- Author
-
Mark P. Purdue, Dazhe Chen, Jason Y.Y. Wong, Xiao-Ou Shu, Andreas Sjödin, Bryan A. Bassig, Yong-Bing Xiang, Jian-Min Yuan, Lawrence S. Engel, Yu-Tang Gao, Renwei Wang, Richard S. Jones, Jennifer M. Adams-Haduch, Hilde Langseth, Wei Hu, Woon-Puay Koh, Bu Tian Ji, Tom Kristian Grimsrud, Wei Zheng, Gong Yang, Qing Lan, Wei Jie Seow, Nathaniel Rothman, Mark D. Davis, and H. Dean Hosgood
- Subjects
Male ,China ,Cancer Research ,Physiology ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Risk Factors ,Hydrocarbons, Chlorinated ,medicine ,Humans ,Prospective Studies ,Pesticides ,Aged ,Singapore ,business.industry ,Lymphoma, Non-Hodgkin ,Polychlorinated biphenyl ,Blood collection ,Middle Aged ,Pesticide ,medicine.disease ,Lymphoma ,Increased risk ,Oncology ,Dichlorodiphenyldichloroethylene ,chemistry ,Case-Control Studies ,030220 oncology & carcinogenesis ,Hodgkin lymphoma ,Environmental Pollutants ,Female ,Conditional logistic regression ,business ,Follow-Up Studies - Abstract
Specific organochlorines (OCs) have been associated with non-Hodgkin lymphoma (NHL) with varying degrees of evidence. These associations have not been evaluated in Asia, where the high exposure and historical environmental contamination of certain OC pesticides (e.g. dichlorodiphenyltrichloroethane (DDT), hexachlorocyclohexane (HCH)) are different from Western populations. We evaluated NHL risk and pre-diagnostic blood levels of OC pesticides/metabolites and polychlorinated biphenyl (PCB) congeners in a case-control study of 167 NHL cases and 167 controls nested within three prospective cohorts in Shanghai and Singapore. Conditional logistic regression was used to analyze lipid-adjusted OC levels and NHL risk. Median levels of p,p’-dichlorodiphenyldichloroethylene (p,p’-DDE), the primary DDT metabolite, and β-HCH were up to 12 and 65 times higher, respectively, in samples from the Asian cohorts compared to several cohorts in the United States and Norway. An increased risk of NHL was observed among those with higher β-HCH levels both overall (3(rd) vs. 1(st) tertile OR=1.8, 95%CI=1.0-3.2; p(trend) =0.049) and after excluding cases diagnosed within two years of blood collection (3(rd) vs. 1(st) tertile OR = 2.0, 95%CI =1.1-3.9; p(trend) = 0.03), and the association was highly consistent across the three cohorts. No significant associations were observed for other OCs, including p,p’-DDE. Our findings provide support for an association between β-HCH blood levels and NHL risk. This is a concern because substantial quantities of persistent, toxic residues of HCH are present in the environment worldwide. Although there is some evidence that DDT is associated with NHL, our findings for p,p’-DDE do not support an association.
- Published
- 2019
6. Circulating isoflavone and lignan concentrations and prostate cancer risk: a meta-analysis of individual participant data from seven prospective studies including 2,828 cases and 5,593 controls
- Author
-
Emily Sonestedt, Peter Wallström, Konstantinos K. Tsilidis, Isabel Drake, Shoichiro Tsugane, Pär Stattin, Kazuya Mikami, Robert Luben, Antonia Trichopoulou, Aurora Perez-Cornago, Paul N. Appleby, Norie Sawada, Tatsuhiko Kubo, Ruth C. Travis, Fulvio Ricceri, Leire Gil, Anders Johansson, Rikard Landberg, Cecilie Kyrø, Akiko Tamakoshi, Hilde Langseth, Neil Murphy, Randi Elin Gislefoss, Naomi E. Allen, Heiner Boeing, Lena Maria Nilsson, Kay-Tee Khaw, Kotaro Ozasa, and Timothy J. Key
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,030109 nutrition & dietetics ,business.industry ,Daidzein ,food and beverages ,Genistein ,Equol ,Lower risk ,medicine.disease ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,chemistry ,Enterolactone ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,Phytoestrogens ,Enterodiol ,business - Abstract
Phytoestrogens may influence prostate cancer development. This study aimed to examine the association between prediagnostic circulating concentrations of isoflavones (genistein, daidzein, equol) and lignans (enterolactone and enterodiol) and the risk of prostate cancer. Individual participant data were available from seven prospective studies (two studies from Japan with 241 cases and 503 controls and five studies from Europe with 2,828 cases and 5,593 controls). Because of the large difference in circulating isoflavone concentrations between Japan and Europe, analyses of the associations of isoflavone concentrations and prostate cancer risk were evaluated separately. Prostate cancer risk by study-specific fourths of circulating concentrations of each phytoestrogen was estimated using multivariable-adjusted conditional logistic regression. In men from Japan, those with high compared to low circulating equol concentrations had a lower risk of prostate cancer (multivariable-adjusted OR for upper quartile [Q4] vs. Q1 = 0.61, 95% confidence interval [CI] = 0.39–0.97), although there was no significant trend (OR per 75 percentile increase = 0.69, 95 CI = 0.46–1.05, ptrend = 0.085); Genistein and daidzein concentrations were not significantly associated with risk (ORs for Q4 vs. Q1 = 0.70, 0.45–1.10 and 0.71, 0.45–1.12, respectively). In men from Europe, circulating concentrations of genistein, daidzein and equol were not associated with risk. Circulating lignan concentrations were not associated with the risk of prostate cancer, overall or by disease aggressiveness or time to diagnosis. There was no strong evidence that prediagnostic circulating concentrations of isoflavones or lignans are associated with prostate cancer risk, although further research is warranted in populations where isoflavone intakes are high.
- Published
- 2018
7. Prospective study of genital human papillomaviruses and nonmelanoma skin cancer
- Author
-
Randi Elin Gislefoss, Kristin Andersson, Anna Söderlund Strand, Joakim Dillner, Hilde Langseth, Tapio Luostarinen, Michael Pawlita, Ola Forslund, and Tim Waterboer
- Subjects
Cervical cancer ,Cancer Research ,Pathology ,medicine.medical_specialty ,integumentary system ,business.industry ,HPV infection ,Odds ratio ,medicine.disease ,Dermatology ,Serology ,Cancer registry ,Oncology ,medicine ,Basal cell carcinoma ,Skin cancer ,business ,Prospective cohort study - Abstract
Genital high-risk human papillomaviruses (HPVs) cause cervical cancer and are also found in a small proportion of nonmelanoma skin cancers (NMSCs). We used cancer registry linkages to follow the 856,000 serum donors included in the Southern Sweden Microbiology Biobank or the Janus Biobank in Norway, for incident skin cancers occurring up to 30 years after serum donation. Serum samples taken before diagnosis of squamous cell carcinoma (SCC) (N = 633), basal cell carcinoma (BCC) (N = 1990) or other NMSC (N = 153) and matched samples from control donors were tested for antibodies to the genital HPV types 16 and 18. Both HPV 16 and 18 were associated with increased risk for SCC [odds ratio (OR) 1.6, 95% confidence interval (CI) 1.1-2.6 and OR 1.7, 95% CI 1.1-2.5, respectively] and other NMSC (OR 2.3, 95% CI 1.0-5.2 and OR 3.5, 95% CI 1.4-8.7, respectively), but not for BCC. Tumor blocks from HPV16 or 18 seropositive cases were tested with real-time polymerase chain reaction for presence of HPV16 or 18 DNA. No HPV18 DNA was found and only four of 79 SCC cases (two of which were from the perineum/perianal area), one of 221 BCC cases and zero of five cases with other NMSC contained HPV16 DNA. In conclusion, we found prospective evidence that HPV16 and 18 antibodies associate with SCC and other NMSC risk, but not with BCC risk. As only a small proportion of seropositive subjects had evidence of the corresponding HPV DNA in the tumor, most of this excess risk is likely to be due to confounders associated with genital HPV infection.
- Published
- 2013
8. Prospective study of genital human papillomaviruses and nonmelanoma skin cancer
- Author
-
Kristin, Andersson, Tapio, Luostarinen, Anna Söderlund, Strand, Hilde, Langseth, Randi E, Gislefoss, Ola, Forslund, Michael, Pawlita, Tim, Waterboer, and Joakim, Dillner
- Subjects
Male ,Human papillomavirus 16 ,Skin Neoplasms ,Human papillomavirus 18 ,Papillomavirus Infections ,Middle Aged ,Antibodies, Viral ,Reproductive Tract Infections ,Carcinoma, Basal Cell ,DNA, Viral ,Carcinoma, Squamous Cell ,Humans ,Female ,Prospective Studies ,Registries ,Aged - Abstract
Genital high-risk human papillomaviruses (HPVs) cause cervical cancer and are also found in a small proportion of nonmelanoma skin cancers (NMSCs). We used cancer registry linkages to follow the 856,000 serum donors included in the Southern Sweden Microbiology Biobank or the Janus Biobank in Norway, for incident skin cancers occurring up to 30 years after serum donation. Serum samples taken before diagnosis of squamous cell carcinoma (SCC) (N = 633), basal cell carcinoma (BCC) (N = 1990) or other NMSC (N = 153) and matched samples from control donors were tested for antibodies to the genital HPV types 16 and 18. Both HPV 16 and 18 were associated with increased risk for SCC [odds ratio (OR) 1.6, 95% confidence interval (CI) 1.1-2.6 and OR 1.7, 95% CI 1.1-2.5, respectively] and other NMSC (OR 2.3, 95% CI 1.0-5.2 and OR 3.5, 95% CI 1.4-8.7, respectively), but not for BCC. Tumor blocks from HPV16 or 18 seropositive cases were tested with real-time polymerase chain reaction for presence of HPV16 or 18 DNA. No HPV18 DNA was found and only four of 79 SCC cases (two of which were from the perineum/perianal area), one of 221 BCC cases and zero of five cases with other NMSC contained HPV16 DNA. In conclusion, we found prospective evidence that HPV16 and 18 antibodies associate with SCC and other NMSC risk, but not with BCC risk. As only a small proportion of seropositive subjects had evidence of the corresponding HPV DNA in the tumor, most of this excess risk is likely to be due to confounders associated with genital HPV infection.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.